Related Experiment Videos
Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy
Tirso Perez-Medina1, José Bajo-Arenas, Javier Haya
1Santa Cristina University Hospital, Universidad Autónoma de Madrid, Madrid, Spain. tperezm@meditex.es
Objective:
To assess the incidence of endometrial polyps during postmenopausal replacement therapy with tibolone, using an appropriate control group.
Design:
A total of 485 postmenopausal women were included in this open, prospective, comparative study for a duration of 36 months. Of this group, 249 women received 2.5 mg/day of tibolone and 244 women served as controls, receiving continuous-combined estrogen-progestogen therapy (HT). Transvaginal ultrasound, hysteroscopy, and directed biopsies were performed before treatment was initiated and at the end of the study.
Results:
Two hundred twenty-one of the women receiving tibolone and 203 receiving continuous-combined HT completed the study. Endometrial polyps were detected in 74 women (33.4%) from the tibolone group and in 22 women (10.8%) from the HT group (P < 0.01). The vaginal bleeding rate did not differ between the groups. The frequency of atrophic polyps was significantly higher in the tibolone group (P < 0.01). No difference was found in the size of the polyps.
Conclusions:
Tibolone increases by threefold the risk for endometrial polyps.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...